Attovia Therapeutics (NASDAQ:ATTO) Stock Price Up 7.5% on Insider Buying Activity

Shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) traded up 7.5% during mid-day trading on Monday following insider buying activity. The stock traded as high as $21.50 and last traded at $21.34. 111,850 shares were traded during trading, a decline of 67% from the average daily volume of 339,314 shares. The stock had previously closed at $19.86.

Specifically, Director Colin Walsh acquired 85,000 shares of Attovia Therapeutics stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $21.00 per share, for a total transaction of $1,785,000.00. Following the completion of the purchase, the director directly owned 85,000 shares in the company, valued at $1,785,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Goldman Sachs Group Inc bought 500,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the acquisition, the insider directly owned 3,020,632 shares of the company’s stock, valued at approximately $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In other news, major shareholder Goldman Sachs Group Inc bought 85,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average price of $21.00 per share, for a total transaction of $1,785,000.00. Following the completion of the transaction, the insider directly owned 85,000 shares in the company, valued at approximately $1,785,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Attovia Therapeutics Stock Up 8.1%

Institutional Trading of Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. increased its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.